CA3 drug Peptide 17 is a term that encompasses several distinct molecules, each with unique research applications and potential therapeutic implications. While the term itself can be broad, the dominant focus in recent scientific literature points towards "YAP-TEAD Inhibitor 1 (Peptide 17)," a potent compound investigated for its role in cancer therapy. However, other "Peptide 17" designations appear in research related to renal injury, antimicrobial activity, and even cosmetic applications. Understanding these different contexts is crucial for appreciating the diverse roles this peptide sequence plays.
The most prominent "Peptide 17" identified is YAP-TEAD Inhibitor 1, a small molecule that acts as a potent inhibitor of the YAP-TEAD protein-protein interaction.IL17A blocking peptide | IL-17 Blocking Peptide-NP_002181 This interaction is a critical component of the Hippo signaling pathway, which plays a significant role in regulating cell growth, proliferation, and differentiation. Dysregulation of the Hippo-YAP pathway is frequently observed in various cancers, making YAP-TEAD Inhibitor 1 a promising candidate for cancer treatment.YAP-TEAD Inhibitor 1 (Peptide 17) | CAS NO.
Research indicates that YAP-TEAD Inhibitor 1 has demonstrated significant efficacy in preclinical studies. It has been shown to possess an IC50 of 25 nM, signifying its potent ability to inhibit the YAP-TEAD interaction. Studies suggest that this inhibition can lead to the activation of crucial cell death signals, such as Bcl2/Bax/caspase-9, ultimately contributing to the suppression of lung cancer cells.Peptide 17 is a inhibitor of this YAP-TEAD protein-protein interactionwhich has potential usage in treatment of YAP-involved cancers with IC50 of 25nM. Furthermore, this peptide has been implicated in mitigating early renal injury associated with hypertension by modulating the Hippo/YAP signaling pathway, potentially offering therapeutic avenues for kidney diseaseCAS|VASOINTESTINAL PEPTIDE, 17-NLE|生产厂家. The compound's ability to disrupt YAP-TEAD interactions is a key focus for researchers exploring novel cancer therapies.
Beyond its role as a YAP-TEAD inhibitor, the "Peptide 17" designation appears in several other research contexts:
* Renal Injury: As mentioned, a peptide designated as "Peptide 17" has shown promise in alleviating early hypertensive renal injury. Studies have demonstrated its capacity to reduce systolic blood pressure and urine protein levels in hypertensive rat models, suggesting a role in managing kidney damage associated with high blood pressure.
* Antimicrobial Activity: TO17 (Teleost Antimicrobial Peptide 17) is a broad-spectrum antimicrobial peptide with immunostimulatory properties. This peptide has potential applications as an antimicrobial agent, particularly in aquaculture.Structure-Based Design and Synthesis of Potent Cyclic ...
* Cosmetic Applications: Myristoyl Pentapeptide-17 is a peptide used in cosmetic products, specifically for promoting eyelash growth. It is described as a five-amino acid peptide attached to myristic acid, enhancing its bioavailability. This peptide is believed to directly stimulate keratin genes, leading to thicker and longer lash growthYAP-TEAD Inhibitor 1 (Peptide 17)产品说明书.
* Erythropoietin Mimetic: EMP17 (Erythropoietin-Mimetic Peptide 17) mimics the function of erythropoietin (EPO), a hormone crucial for red blood cell production.This peptide corresponds to17 amino acids near the carboxy terminus of human TACE. PEP-0008 can be used as a blocking peptide with polyclonal antibody PA5- ... EMP17 activates its receptor by binding to its extracellular domain, thereby stimulating the production of red blood cells.
* Vasoactive Peptides: Vasointestinal Peptide, 17-NLE, is another peptide identified, though its specific role within the broader "Peptide 17" context is less defined by the provided information.
* Cytokeratin 17: Monoclonal antibodies targeting Cytokeratin 17 are also mentioned, indicating research into this specific protein, which is a component of epithelial cells.Peptide 17 is aYAP-TEAD protein-protein interaction inhibitorwhich has potential usage in treatment of YAP-involved cancers with IC50 of 25 nM.
Given the varied applications, it is essential to distinguish between these different "Peptide 17" entities based on their full names and documented functions.YAP-TEAD Inhibitor 1 (Peptide 17) 是YAP-TEAD间蛋白相互作用的抑制剂，在YAP相关的癌症中有其潜在应用价值，IC50为25 nM。 YAP-TEAD Inhibitor 1 (Peptide 17) is primarily recognized for its role in cancer research and signaling pathway modulation. Other peptides, like Myristoyl Pentapeptide-17 or TO17, have distinct functionalities in cosmetics and antimicrobial applications, respectively. Researchers and consumers alike should pay close attention to the specific designation to ensure accurate understanding and applicationTiger17 peptide. The commonality of the "17" in their names can lead to confusion, but their scientific and commercial applications are quite distinct.
The ongoing research into YAP-TEAD Inhibitor 1 (Peptide 17) underscores its potential as a therapeutic agent for various cancers. Further clinical trials are anticipated to validate its efficacy and safety in human patientsA five amino acid peptide(Lys-Leu-Ala-Lys-Lys) attached to the oil-soluble fatty acid, myristic acid for better bioavailability.. Similarly, the exploration of Peptide 17 in mitigating renal injury could pave the way for new treatments for hypertension-related kidney disease(S8164) YAP-TEAD Inhibitor 1 (Peptide 17). While some applications, like cosmetic peptides, are already established, the fundamental research into the biological roles and therapeutic potential of various "Peptide 17" molecules continues to expand, highlighting the versatility and significance of these peptide sequences in scientific discovery.Human ADAM17 Synthetic Peptide (PEP-0008)
Join the newsletter to receive news, updates, new products and freebies in your inbox.